Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24186456 | 1.00 | HTR2A (0.37) | HTR2AHTR2CHTR2BADRA2AADRA2B | |
| SCHEMBL29924349 | 1.00 | HTR2A (0.37) | HTR2AHTR2CHTR2BADRA2AADRA2B | |
| SCHEMBL23980935 | 0.90 | CYP11B1 (0.39) | HTR2AHTR2CHTR2BADRA2AADRA2B | |
| SCHEMBL30275367 | 0.90 | CYP11B1 (0.39) | HTR2AHTR2CHTR2BADRA2AADRA2B | |
| SCHEMBL30680666 | 0.88 | MAP3K14 (0.41) | HTR2AHTR2CHTR2BADRA2AADRA2B | |
| SCHEMBL29149833 | 0.87 | PTGS1 (0.35) | HTR2AHTR2CHTR2BHTTFFAR1 | |
| SCHEMBL29149759 | 0.87 | PTGS1 (0.35) | HTR2AHTR2CHTR2BHTTFFAR1 | |
| SCHEMBL29924327 | 0.87 | PTGS1 (0.35) | HTR2AHTR2CHTR2BHTTFFAR1 | |
| SCHEMBL29924595 | 0.87 | PTGS1 (0.35) | HTR2AHTR2CHTR2BHTTFFAR1 | |
| SCHEMBL29924339 | 0.82 | HTT (0.43) | HTR2AHTR2CHTTNPC1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552791-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4143183-B1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2025-10-22 | — | — | EP | disclosed |
| US-20250214999-A1 | HETEROCYCLIC GLP-1 AGONISTS | SHOUTI INC. | 2025-07-03 | — | — | US | disclosed |
| CN-117986264-A | Benzo nitrogen-containing polycyclic derivative regulator and preparation method and application thereof | 江苏豪森药业集团有限公司 | 2024-05-07 | — | — | CN | disclosed |
| CN-117177970-A | Polycyclic derivative regulator, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2023-12-05 | — | — | CN | disclosed |
| US-20230322756-A1 | FUSED IMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2023-10-12 | — | — | US | disclosed |
| US-20230322756-A1 | FUSED IMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2023-10-12 | — | — | US | disclosed |
| US-20230295154-A1 | HETEROCYCLIC GLP-1 AGONISTS | SHOUTI INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295154-A1 | HETEROCYCLIC GLP-1 AGONISTS | SHOUTI INC. | 2023-09-21 | — | — | US | disclosed |
| EP-4209490-A1 | FUSED IMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2023-07-12 | — | — | EP | disclosed |
| CN-115884969-A | Condensed imidazole derivative, preparation method and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2023-03-31 | — | — | CN | disclosed |
| WO-2022007979-A1 | FUSED IMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | 江苏恒瑞医药股份有限公司 | 2022-01-13 | — | — | WO | disclosed |
| WO-2021219019-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295154-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | HTR2A 181/4885HTR2C 160/4885HTR2B 206/4885 |
| US-12552791-B2 | Heterocyclic GLP-1 agonists | GLP1R, NPY1R, NPY2R | HTR2A 436/4885HTR2C 191/4885HTR2B 418/4885 |
| US-20230322756-A1 | FUSED IMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | GLP1R, GIPR, VIP | HTR2A 2291/4885HTR2C 1768/4885HTR2B 1625/4885 |
| US-20250214999-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | HTR2A 181/4885HTR2C 160/4885HTR2B 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.